drugset

drugset / Trial / NCT00426972

Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites

NCT00426972 ↗

Phase 3 Completed 148 enrolled Renovo

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial will assess the effects of Zesteem (estradiol) on the healing of split thickness skin graft donor sites in patients aged 18-85 years.

Timeline

Start: 2007-01
Primary completion: 2008-07
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Estradiol	Other / unclassified	—	—

Indications